Skip to main content

Table 3 The contribution of the A. maurorum to the body weight, prostate weight, and prostate enlargement indices in rats with benign prostatic hyperplasia. The obtained results have been presented as mean ± SD

From: Protective effect of the hydroethanolic extract of camelthorn (Alhagi maurorum) on benign prostatic hyperplasia induced by testosterone in rats

 

Initial BW (g)

Final BW (g)

PW (mg)

PI (mg/g)

% inhibition for PI

Sham C.

251 ± 8.49

290 ± 11.55a

509.8 ± 72.42a

1.76 ± 0.23a

-

BPH

245 ± 8.94

234 ± 10.02b,*

1564.67 ± 249b,*

6.73 ± 1.34b,*

-

Finasteride

242 ± 15.71

269 ± 15.9a

596.67 ± 77.18a,#

2.23 ± 0.37a,#

90.4

Alhagi (200)

240 ± 4.42

265 ± 8.15a

764.6 ± 115.37a,#

2.89 ± 0.43a,#

77.3

Alhagi (400)

238 ± 16.41

275 ± 30.87a

539 ± 91.76a,#

1.97 ± 0.37a,#

95.7

  1. Sham C sham control, BPH: positive control with benign prostatic hyperplasia, Finasteride: comparative control, the BPH animals receiving Finasteride with a dosage of 5 mg/kg/day through oral gavages, and Alhagi (200) and Alhagi (400): the BPH animals receiving A. maurorum extract at a dosage of 200 and 400 mg/kg/day through oral gavage for 28 successive days
  2. BW Body weight, PW Prostate weight, PI Prostatic index and % inhibition for PI: inhibition percentage for the prostatic index
  3. The values characterized by various letters in a column indicate a significant difference (p < 0.05). Furthermore, the values shown by a * sign indicate a significant difference of p < 0.0001 compared to the sham control, while the values with a # sign refer to a significant difference of p < 0.0001 compared to the BPH model. It is noteworthy that statistical analysis was not applicable to % inhibition for the prostatic index